I would say Pcaruso, this type of investment is not in the realm of your expertise.A couple of quotes from our CMO Dr. Mitchell Glass.
"People who invest in biotechs, whether public or private, should expect to lose their money," said Dr. Mitchell Glass, Invion's chief medical officer and vice president of research and development. "This is not a game for the faint-hearted or people betting their retirement income. These are, at the best of times, speculative opportunities that only get more expensive as you go forward."
"Very successful biotech companies don't show black ink," Glass said. "And as we progress, we'll generate more and more red ink until someone steps in."
"A year earlier, AstraZeneca acquired Pearl Therapeutics for up to $1.15 billion after the private, California-based company raised $232 million over six years to take a repurposed generic to late-stage trial for the treatment of COPD.
Chris Yochim, a former head of external relations for AstraZeneca and the current chairman of the Delaware BioScience Association, said Invion is well positioned to follow suit."
Full article available
Invion betting big on future drug breakthroughs
(20min delay)